Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
Abstract Background Adjuvant endocrine therapy undoubtedly prolongs the time to recurrence for patients with hormone-positive early breast cancer. Extended endocrine therapy to 10 years or longer has been expected to bring a greater clinical advantage. However, the related research conclusions are c...
Main Authors: | Li Li, Bingmei Chang, Xiaoyue Jiang, Xueke Fan, Yingrui Li, Teng Li, Shanshan Wu, Jun Zhang, Seyed Kariminia, Qin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-10-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4878-4 |
Similar Items
-
Adverse effects of adjuvant endocrine therapy
by: E. I. Kovalenko, et al.
Published: (2018-07-01) -
The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy
by: Giorgio Dell’Acqua, et al.
Published: (2020-11-01) -
Adjuvant hormone therapy in postmenopausal patients with locally advanced breast cancer: hope and reality
by: V. I. Borisov
Published: (2014-07-01) -
Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions
by: Brittany Humphries, et al.
Published: (2018-06-01) -
Neoadjuvant endocrine treatment of women with breast cancer
by: Julian Iturbe, et al.
Published: (2011-09-01)